Jim Simons’s Fate Therapeutics FATE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $3.57M | Buy |
2,974,683
+613,802
| +26% | +$747K | 0.01% | 1560 |
|
|
2025
Q4 | $2.32M | Buy |
2,360,881
+1,098,366
| +87% | +$1.32M | ﹤0.01% | 1772 |
|
|
2025
Q3 | $1.59M | Buy |
1,262,515
+1,048,052
| +489% | +$1.13M | ﹤0.01% | 2218 |
|
|
2025
Q2 | $240K | Buy |
+214,463
| New | +$249K | ﹤0.01% | 3113 |
|
|
2025
Q1 | – | Sell |
-378,619
| Closed | -$625K | – | 3569 |
|
|
2024
Q4 | $625K | Buy |
378,619
+16,000
| +4% | +$40.3K | ﹤0.01% | 2747 |
|
|
2024
Q3 | $1.27M | Sell |
362,619
-185,925
| -34% | -$723K | ﹤0.01% | 2306 |
|
|
2024
Q2 | $1.8M | Buy |
+548,544
| New | +$2.4M | ﹤0.01% | 1943 |
|
|
2023
Q4 | – | Sell |
-109,219
| Closed | -$232K | – | 3829 |
|
|
2023
Q3 | $232K | Sell |
109,219
-563,097
| -84% | -$1.87M | ﹤0.01% | 3041 |
|
|
2023
Q2 | $3.2M | Sell |
672,316
-660,603
| -50% | -$3.65M | ﹤0.01% | 1689 |
|
|
2023
Q1 | $7.6M | Sell |
1,332,919
-472,017
| -26% | -$2.85M | 0.01% | 1240 |
|
|
2022
Q4 | $18.2M | Buy |
1,804,936
+1,267,417
| +236% | +$23.8M | 0.02% | 754 |
|
|
2022
Q3 | $12M | Buy |
+537,519
| New | +$15.5M | 0.02% | 930 |
|
|
2022
Q2 | – | Sell |
-45,319
| Closed | -$1.76M | – | 4326 |
|
|
2022
Q1 | $1.76M | Buy |
+45,319
| New | +$1.75M | ﹤0.01% | 2328 |
|
|
2021
Q3 | – | Sell |
-34,719
| Closed | -$3.01M | – | 3571 |
|
|
2021
Q2 | $3.01M | Buy |
+34,719
| New | +$2.8M | ﹤0.01% | 1970 |
|
|
2020
Q4 | – | Sell |
-51,619
| Closed | -$2.06M | – | 3481 |
|
|
2020
Q3 | $2.06M | Buy |
+51,619
| New | +$1.8M | ﹤0.01% | 2109 |
|
|
2019
Q3 | – | Sell |
-11,819
| Closed | -$240K | – | 3498 |
|
|
2019
Q2 | $240K | Sell |
11,819
-67,843
| -85% | -$1.22M | ﹤0.01% | 3254 |
|
|
2019
Q1 | $1.4M | Buy |
+79,662
| New | +$1.26M | ﹤0.01% | 2509 |
|
|
2018
Q4 | – | Sell |
-95,100
| Closed | -$1.55M | – | 3439 |
|
|
2018
Q3 | $1.55M | Buy |
+95,100
| New | +$1.12M | ﹤0.01% | 2405 |
|
|
2018
Q2 | – | Sell |
-40,100
| Closed | -$391K | – | 3344 |
|
|
2018
Q1 | $391K | Sell |
40,100
-105,100
| -72% | -$1.01M | ﹤0.01% | 2984 |
|
|
2017
Q4 | $887K | Sell |
145,200
-74,700
| -34% | -$333K | ﹤0.01% | 2709 |
|
|
2017
Q3 | $871K | Sell |
219,900
-88,900
| -29% | -$302K | ﹤0.01% | 2618 |
|
|
2017
Q2 | $1M | Buy |
308,800
+13,100
| +4% | +$50.2K | ﹤0.01% | 2555 |
|
|
2017
Q1 | $1.34M | Buy |
295,700
+85,800
| +41% | +$314K | ﹤0.01% | 2431 |
|
|
2016
Q4 | $527K | Buy |
209,900
+21,900
| +12% | +$58.6K | ﹤0.01% | 2745 |
|
|
2016
Q3 | $587K | Buy |
188,000
+7,300
| +4% | +$17.7K | ﹤0.01% | 2762 |
|
|
2016
Q2 | $307K | Sell |
180,700
-42,000
| -19% | -$76.1K | ﹤0.01% | 2938 |
|
|
2016
Q1 | $401K | Buy |
222,700
+134,200
| +152% | +$276K | ﹤0.01% | 2907 |
|
|
2015
Q4 | $298K | Sell |
88,500
-4,100
| -4% | -$17.2K | ﹤0.01% | 2885 |
|
|
2015
Q3 | $494K | Buy |
92,600
+11,880
| +15% | +$81.1K | ﹤0.01% | 2634 |
|
|
2015
Q2 | $522K | Buy |
80,720
+65,820
| +442% | +$394K | ﹤0.01% | 2706 |
|
|
2015
Q1 | $73K | Buy |
+14,900
| New | +$73.8K | ﹤0.01% | 3043 |
|
Other funds holding FATE
RG
VCM
VPM
JJ
Jim Simons's FATE Position: Q1 2026 in Review
Jim Simons increased its Fate Therapeutics (FATE) stake by 26% in Q1 2026, buying an estimated $747K and bringing the position to 2,974,683 shares worth $3.57M. The position accounts for 0.01% of the portfolio, ranked #1560.
Jim Simons first reported a position in FATE in Q1 2015 and has held it in 31 quarters since. The position peaked at $18.2M in Q4 2022. 158 funds tracked by Wall St. Rank hold FATE as of Q1 2026.
- Jim Simons held 2,974,683 shares of Fate Therapeutics worth $3.57M as of Q1 2026.
- Jim Simons bought 613,802 Fate Therapeutics shares in Q1 2026, an estimated $747K.
- Fate Therapeutics made up 0.01% of Jim Simons's portfolio in Q1 2026, its #1560 holding.
- Jim Simons first reported a position in Fate Therapeutics in Q1 2015 and has held it in 31 quarters since.
- Jim Simons's Fate Therapeutics position peaked at $18.2M in Q4 2022.
- 158 funds tracked by Wall St. Rank held Fate Therapeutics as of Q1 2026.
Based on Renaissance Technologies's 13F filing for Q1 2026, filed 14 May 2026.